Encysive Avoids Additional Trials For Thelin Resubmission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Encysive Pharmaceuticals has relied on existing data to address lingering FDA concerns regarding the pulmonary arterial hypertension drug Thelin, the company said May 25, following discussions with the agency.